Value of Surveillance Culture in Predicting Causative Pathogens of Septicemia after Allogeneic Hematopoietic Stem Cell Transplantation  by Tanaka, Y. et al.
Poster Session-I 93Patient and Methods: Retrospective analysis of transplant out-
comes in patients with AML/MDS patients who underwent an allo-
geneic transplant with peripheral blood or bone marrow from
a sibling or unrelated donor transplant during the year 2006 at
MDACC, had a pre-SCT F level determined and were alive and dis-
ease free at 90 days post HSCT.
Results: A total of 106 patients with AML/MDS underwent allo-
geneic transplant during that time period of which 90 patients were
alive without relapse by day 90 and complete data including pre
HSCT F levels were available for 77 patients. Patient characteristics
and relationship of pre SCT F on transplant outcomes in patients
surviving at least 90 days is summarized in Table 1. Patients with
the lowest pre SCT-F levels (ie Q1) had the best outcomes when
compared to patients with higher levels (Q2-Q4) . There was a trend
towards improved survival in patients with the lowest level of F pre
SCT when compared to the other patients (p 5 0.09). All patients
had a significant increase in their F levels by D90 post SCT when
compared to Pre SCT.
Conclusions: Pre SCT F levels may still have an impact in SCT
events that happen 3 months after transplant. This together with
continuous rise in F levels post SCT support further studies of
iron chelation therapy post SCT.
Results
1st Quartile F 2nd-4th Quartile F
(\1027 ng/dl) (1028-6714 ng/dl) p valueN 20 57
Median Age (range) 49 (22-70) 53 (21-68) 0.7
%PBSC 90 63 0.02
%Sib Donor 61 33 0.04
%RIC 45 53 0.6
% Remission @ SCT 55 44 0.4
OS @ 1 year 85% 62% 0.09
CGVHD @ 18m 46% 32% 0.08
%NRM @ 1 year 10 18 0.4
F level @ 3 months 1648 (108-5316) 2971 (1134-15437) 0.02255
TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTION IN ADULT
PATIENTS WITH HEMATOLOGIC MALIGNANCIES ON AN INSTITUTION-
SPECIFIC GUIDELINE
Wong, E., Kuyumjian, A.G., Wynd, M.A., Surowiec, D., DeSevo, G.M.,
Patel, A.A., Munk, G., Sebti, R. Hackensack University Medical Center,
Hackensack, NJ
Background: Respiratory syncytial virus (RSV) infections are
associated with increased mortality in patients with hematologic
malignancies. A guideline was developed by the Antimicrobial Stew-
ardship Program with an interdisciplinary approach to facilitate the
treatment of RSV-infections. The objective of this study is to
describe the outcome of RSV-infected adult patients with hemato-
logic malignancies since the implementation of this guideline.
Methods: A retrospective chart review was conducted on RSV-
infected patients$18 years old and treated with aerosolized ribavirin
6 intravenous palivizumab during the period of September 2006
through May 2008. Infections were confirmed by rapid antigen
detection immunoassay and tissue culture inoculation of nasopha-
ryngeal swab specimens. Data collection included: patient demo-
graphics, clinical presentation, diagnostic studies, time-elapsed
post-hematopoietic stem cell transplant (if applicable), treatment
administered, and 30 and 90 day mortality.
Results: Of the 26 patients identified, 13 had upper respiratory
tract infection only and 13 had upper and lower respiratory tract
infection. The mean age (6 SD) was 51.5 6 11 years. Twenty-one
patients were hematopoietic stem cell transplant recipients (13 allo-
geneic, 8 autologous). All patients received aerosolized ribavirin.
Thirteen patients received aerosolized ribavirin plus intravenous
palivizumab. The treatment of 20 patients was consistent with the
institution’s guideline. Within 30 and 90 days of RSV diagnosis,
the mortality was 0 and 2 patients, respectively. Neither death was
attributed to RSV.Conclusion: An institution-specific treatment guideline offers
a systematic approach to the management of RSV-infected adult
patients and may improve RSV-related outcomes.256
EFFECT OF RED BLOOD CELL STORAGE AGE ON OUTCOMES IN NON-
HODGKIN LYMPHOMA PATIENTS RECEIVING AUTOLOGOUS STEM CELL
TRANSPLANTATION
Ramaekers, R.C., Loberiza, F.R., Bierman, P.J., Landmark, J.D. Uni-
versity of Nebraska Medical Center, Omaha, NE
Conflicting literature exists on whether the storage age of red
blood cells (RBC) prior to transfusion affects patient outcomes. In
the setting of cardiac surgery, it was found that RBC’s stored longer
than 15 days prior to transfusion resulted in inferior outcomes. We
evaluated the influence of RBC storage age on patient outcomes after
autologous stem cell transplantation (ASCT).We conducted a retro-
spective cohort study of 361 consecutive patients requiring RBC
support after undergoing first ASCT for non-Hodgkin lymphoma
(NHL) between 2000 and 2006 at the University of Nebraska
Medical Center. Consistent with other studies, the main variable
we evaluated was the maximum age of transfused RBC’s, dichoto-
mized according to median storage age. Patient-, disease-, and treat-
ment-related variables were compared according to median
maximum age of RBC transfused (#34 vs..34 days) usingWilcoxon
and Chi-square tests. Cox proportional hazards regression analysis
was used to assess whether storage duration of RBC’s was associated
with transplant outcome. A total of 191 (53%) and 170 (47%)
patients received RBC transfusion from blood with maximum stor-
age age of #34 days (younger) and .34 days (older), respectively.
Patients receiving older RBC transfusion were likely to be older,
had a longer interval from NHL diagnosis to transplantation, had
more advanced disease at NHL diagnosis, and were more likely to
be in relapse at the time of transplantation. Patients in the younger
RBC’s group were transfused fewer units (median 3 vs. 5; P 5
\0.001) and had a significantly lower median age of all units trans-
fused (21 vs. 32 days; P 5 \0.001). There were no differences
between the younger and older transfused groups in terms of median
length of hospital stay (12 vs. 13 days; P 5 0.13), 100-day survival
rate (94% vs. 94%; P 5 0.96), or 1-year overall survival (85% vs.
85%; P 5 0.90). After adjusting for significant prognostic variables
in the multivariate analysis, the risk of death for patients transfused
with older blood was not significantly different from those receiving
younger RBC’s (Hazard Ratio 0.96; 95%CI 0.65–1.42, P5 0.85). In
conclusion, our single-institution cohort analysis of NHL patients
undergoing ASCT failed to demonstrate any significant differences
in outcomes according to the storage age of transfused RBC’s.257
VALUE OF SURVEILLANCE CULTURE IN PREDICTING CAUSATIVE PATHO-
GENS OF SEPTICEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Tanaka, Y.1, Kiuchi, K.1, Kudo, M.1, Kurotori, T.1, Yamamoto, S.1,
Tsujimura, N.1, Yamada, K.1, Yashima, T.1, Mori, T.2, Okamoto, S.2
1Keio University Hospital, Tokyo, Japan; 2Keio University School of Med-
icine, Tokyo, Japan
Background: Recipients of allogeneic hematopoietic stem cell
transplantation (HSCT) are susceptible to fatal bacterial infection
because of long-term severe neutropenia and mucositis. Initiating
an appropriate antimicrobial therapy immediately on developing
bacterial infection is essential for improving survival. Surveillance
culture can be used as a useful additional measure in themanagement
of infection by predicting the causative pathogen. In the present
study, we have evaluated the value of surveillance culture in septice-
mia diagnosed after allogeneic HSCT.
Patients and Methods: Among 116 recipients of allogeneic
HSCT performed for hematological diseases at Keio University
Hospital, 40 episodes of septicemia were observed. All patients had
received ciprofloxacin (600 mg/day) and fluconazole (200 mg/day)
orally for the prophylaxis of bacterial and fungal infection starting
14 days before HSCT. Surveillance culture was performed by
obtaining samples from the throat and feces once weekly, starting
94 Poster Session-I3 or 4 weeks before HSCT and continued until discharge. All mi-
crobes including normal flora were specified and their susceptibility
profiles to antimicrobial agents were examined. The sensitivity for
the surveillance culture was defined as the rate of detecting microbes
identical to pathogens of septicemia from throat or feces at least 1
week before the development of septicemia.
Results: Causative pathogens were gram-positive cocci (GPC)
in 19, gram-positive rods (GPR) in 5, and gram-negative rods
(GNR) in 16 episodes. The sensitivity for surveillance cultures
in detecting causative pathogens of septicemia prior to the devel-
opment of septicemia was 42.5% (17 of 40) in all episodes. The
sensitivity was 73.7% (14 of 19) in the septicemia due to GPC,
which was significantly higher than that due to GNR (18.8%; 3
of 16, p\ 0.01).
Conclusions: We conclude that weekly surveillance culture is
useful in predicting the pathogen causing septicemia, particularly
in septicemia due to GPC, after allogeneic HSCT.258
HEMORRHAGIC CYSTITIS (HC) IN HEMATOPOIETIC STEM CELL TRANS-
PLANT (HSCT) RECIPIENTS USING ABLATIVE FLUDARABINE/BUSULFAN
(FB) CONDITIONING WITH AND WITHOUT TOTAL BODY IRRADIATION
(TBI)
Haq, B.1, Sahovic, E.A.1, Rossetti, J.M.1, Shadduck, R.K.1, Atem, F.2,
Lister, J.1 1Western Pennsylania Cancer Institute, Pittsburgh, PA; 2Uni-
versity of Pittsburgh, Pittsburgh, PA
HC is a recognized complication of HSCT, commonly associ-
ated with the use of cyclophosphamide. Ninety one patients under-
went non-cyclophosphamide, intravenous FB conditioning for
HSCT (autologous [AUTO], n 5 11; matched unrelated donor
[MUD], n 5 42; matched related donor [MRD], n 5 38) at our
institution from February 2005 to September 2008. The condi-
tioning regimen consisted of fludarabine 50 mg/m2 /day (5 days),
busulfan 3.2 mg/kg/day (4 days) with or without TBI (200 cGy x
2). Urine was tested for BK virus using electron microscopy or
polymerase chain reaction in most patients who developed HC.
Twenty seven patients received FB with TBI (AUTO, n 5 4,
MUD, n 5 7, MRD, n 5 16) whereas 64 patients received FB
without TBI (AUTO, n 5 7, MUD, n 5 35, MRD, n 5 22). Me-
dian age was 48.6 years (range: 22–81); male: female ratio was
1.7:1. 17% patients developed HC within one year of transplanta-
tion. 6/27 (22%) of patients who received FB with TBI developed
HC whereas 10/64 (16%) of those that received FB alone devel-
oped HC. All patients who developed HC had an allogeneic trans-
plant (MUD, n 5 8; MRD, n 5 8). The median time to
presentation was 36 days post transplant (range: 14–67). HC cases
were graded as follows: grade 1(n 5 4), grade 2(n 5 9), grade 3(n
5 2), grade 4(n 5 1). BKViruria was detected in 12/16 (75%) of
patients with HC. Acute graft versus host disease grade 2–4 was
seen in 4/16 patients. 1/16 patient required urological intervention
(bilateral ureteral stent placement), the rest were treated conserva-
tively. There was no mortality from HC. Addition of TBI to the
FB regimen did not increase the incidence of HC (p 5 0.29).
HC appears to be associated with allogeneic HSCT. HC was
mild to moderate (grade 1–3) in most patients. The late onset of
HC, in our study, suggests that the causative agent was reactivation
of BKV and not direct toxicity from the conditioning regimen,
which typically causes early onset HC.Patient Characteristics and their Association with HC
Patients (n) HC, n (%) P valueAUTO 11 0
MRD 38 8 (21) 0.29
MUD 42 8 (19)
Patient age, years
#48 34 5 (14) 0.047
$48 57 11 (19)Conditioning Regimen
FB 64 10 (16) 0.29
FB 1TBI 27 6 (22)259
A PILOT STUDY OF PROPHYLACTIC LIPOSOMAL AMPHOTERICIN B (AM-
BISOME) FOLLOWED BY MICAFUNGIN (MYCAMINE) FOR 100 DAYS
TO PREVENT INVASIVE MOLD INFECTIONS FOLLOWING ALLOGENEIC
STEM CELL TRANSPLANTATION IN PEDIATRIC RECIPIENTS
El-Mallawany, N.K.1, Tallamy, B.1, Fearon, N.1, van de Ven, C.1,
Bhatia, M.1, George, D.1, Satwani, P.1, Cairo, M.S.1,2,3 1Columbia Uni-
versity, New York, NY; 2Columbia University, New York, NY; 3
Columbia University, New York, NY
Invasive mold infections (IMI) are a significant cause of infec-
tious mortality post allogeneic stem cell transplant (AlloSCT).
We have previously demonstrated the safety and efficacy of liposo-
mal amphotericin B (AMB) for 100 days post AlloSCT in pediatric
recipients (Roman/Cairo et al PBC, 2008). Although AMB is safe
and effective for prophylaxis against IMI post AlloSCT, its associ-
ated nephrotoxicity results in its discontinuation in .10% of
patients. Micafungin is a broad spectrum antifungal active against
yeasts and molds with a markedly diminished side effect profile.
We initiated a pilot study to determine the efficacy and safety of
sequential AMB and Micafungin for antifungal prophylaxis in
pediatric AlloSCT recipients. Twenty-seven patients were given
AMB (3mg/kg/day) IV from d 0–45 and transitioned to Micafun-
gin (1mg/kg/day) IV at d 45 if \ grade II acute graft-
versus-host-disease (GVHD), until d 100. GVHD prophylaxis
was tacrolimus and mycophenolate mofetil (n 5 21) for all patients
as we have previously described (Osunkwo/Cairo et al BBMT,
2004) except those who received CD-34 selected PBSC (T-de-
pleted) who received tacrolimus only (n 5 6). Median age: 8 years
(1–23). Gender: 9F, 18M. Diagnoses: 5-ALL, 6-AML, 2-NHL,
1-NBL, 1-HLH, 4-SAA, 1-b-Thal, 1-MAS, 4-SCD, 1-FA, 1-ALD.
There were 8 CB donors (7-unrelated, 1-related), 6 UPBSC
donors, 11 RBM donors and 2 URBM donors. Median follow-
up is 203 days. The median switch day to Micafungin was 47.
There were no reported side effects attributable to Micafungin
and no one discontinued Micafungin due to toxicity. The probabil-
ity of developing $ grade II acute GVHD and extensive chronic
GVHD was 22.2% and 6.3%, respectively. The probability of
IMI was zero. There were 2 documented invasive fungal infections
(IFI) with Candida Parapsilosis (7.4%) and no Aspergillus IMI.
One IFI occurred on AMB prior to switching to Micafungin, the
other occurred 51 days after switching to Micafungin. All patients
in this cohort are alive at the time of data analysis. Despite a high
population of 60% unrelated donors with 25% receiving T-de-
pleted sources, these preliminary results suggest successive antifun-
gal prophylaxis with AMB and Micafungin is tolerable and
effective in preventing IMI, especially Aspergillus, during the first
100 days post AlloSCT in pediatric recipients. Larger randomized
studies are needed to compare the sequential combination of
AMB/Micafungin to other standard antifungal prophylaxis
regimens.260
LOW INFECTIOUS COMPLICATION RATES IN HEMATOPOIETIC STEM
CELL TRANSPLANTATION (HSCT) RECIPIENTS: BENEFITS OF AMONTHLY
MONITORING SYSTEM
Kindwall-Keller, T.L.1, Cooper, B.W.1, Laughlin, M.J.1, Gerson, S.L.1,
Barr, P.1, Parker, P.2, Jacobs, M.R.3, Creger, R.J.1, Lazarus, H.M.1
1University Hospitals of Cleveland, Case Medical Center, Cleveland,
OH; 2University Hospitals of Cleveland, Case Medical Center, Cleveland,
OH; 3University Hospitals of Cleveland, Case Medical Center, Cleveland,
OH
Life-threatening infections are a common cause of morbidity
and mortality in HSCT recipients. We developed a prospective,
real-time monitoring system for infection reporting and interven-
tion for our inpatient HSCT unit. All positive blood, urine, spu-
tum, skin, and stool cultures as well as Clostridium difficile toxin
tests are reviewed monthly. We use an antibiotic algorithm specific
to our HSCT patients (pts) and an on-going antibiotic restriction
policy has been in place for .25 years. All infections are reviewed
to assess the antimicrobial susceptibility patterns of causative in-
fectious agents and to ensure strict compliance with the antibiotic
algorithm. We performed 995 consecutive HSCT from 1994–
